Table 3.
Univariate and multivariate analyses of recurrence-free survival in the present study.
| Characteristics | Univariate analysis | Multivariate analysis (step) | ||
|---|---|---|---|---|
| HR [95%CI] | P-value | HR [95%CI] | P-value | |
| AGE | ||||
| >50 years | Reference | |||
| ≤50 years | 1.05 [0.62, 1.76] | 0.867 | − | − |
| PRIMARY ORGAN | ||||
| Bladder | Reference | |||
| Kidney | 0.73 [0.34, 1.56] | 0.421 | − | − |
| Other | 0.49 [0.15, 1.59] | 0.234 | − | − |
| Paratesticular | 0.62 [0.28, 1.36] | 0.232 | − | − |
| Prostate | 0.95 [0.35, 2.59 | 0.923 | − | − |
| GENDER | ||||
| Female | Reference | |||
| Male | 0.77 [0.40, 1.45] | 0.414 | − | − |
| SYMPTOM AT PRESENTATION | ||||
| No | Reference | Reference | ||
| Yes | 3.63 [0.85, 15.43] | 0.081 | 3.76 [1.06, 13.32] | 0.040 |
| SYMPTOM DURATION | ||||
| >1month | Reference | |||
| ≤1month | 1.14 [0.66, 1.96] | 0.633 | − | − |
| TUMOR SIZE | ||||
| >5cm | Reference | Reference | ||
| ≤5cm | 1.95 [1.00, 3.79] | 0.050 | 1.88 [1.07, 3.29] | 0.028 |
| HISTOLOGICAL SUBTYPE | ||||
| Liposarcoma | Reference | |||
| Leiomyosarcoma | 1.12 [0.54, 2.31] | 0.766 | − | − |
| Other | 1.56 [0.69, 3.55] | 0.285 | − | − |
| Rhabdomyosarcoma | 2.58 [0.98, 6.80] | 0.055 | − | − |
| METASTASIS_AT_ENTRY | ||||
| No | Reference | |||
| Yes | 0.97 [0.53, 1.74] | 0.907 | − | − |
| GRADE | ||||
| High | Reference | |||
| Low | 1.16 [0.58, 2.31] | 0.669 | − | − |
| SURGERY STATUS | ||||
| Surgery and margin negative | Reference | Reference | ||
| Surgery and margin positive | 8.54 [3.98, 18.34] | <0.001 | 6.55 [3.42, 12.54] | <0.001 |
| CHEMOTHERAPY | ||||
| No | Reference | |||
| Yes | 0.90 [0.49, 1.63] | 0.723 | − | − |
| RADIOTHERAPY | ||||
| No | Reference | |||
| Yes | 0.63 [0.34, 1.17] | 0.142 | − | − |
Other in Primary organ included four genitourinary sites: ureter, seminal vesicles, and urethra. Other in histological subtype included Ewing’s sarcoma, primitive neuroectodermal tumor, synovial sarcoma, angiosarcoma, fibrosarcoma, malignant peripheral sheath tumor, myo-fibroblastic tumor, osteosarcoma, chondrosarcoma, and undifferentiated sarcoma.